FDA
Approves Afrezza to Treat Diabetes
"Afrezza is a
new treatment option for patients with diabetes requiring mealtime
insulin," said Jean-Marc Guettier, M.D., director of the Division of
Metabolism and Endocrinology Products in the FDA’s Center for Drug Evaluation
and Research.
CLICK
HERE for the original article.
No comments:
Post a Comment